Cytokines as adjuvants for avian vaccines

Immunology and Cell Biology

Volumn 82, Issue 6, 2004, Pages 638-643

  Asif, Manija ^a   Jenkins, Kristie A ^a   Hilton, Louise S ^a   Kimpton, Wayne G ^b   Bean, Andrew G D ^a   Lowenthal, John W ^a  

^a CSIRO   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adjuvant; Chicken; Cytokine; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; AVIAN VACCINE; CHICKEN MYELOMONOCYTIC GROWTH FACTOR; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT CHICKEN ALPHA INTERFERON; RECOMBINANT CHICKEN GAMMA INTERFERON; RECOMBINANT CHICKEN INTERLEUKIN 1BETA; RECOMBINANT CHICKEN INTERLEUKIN 2; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; VACCINE;

ANTIVIRAL ACTIVITY; AUTOMATION; BIRD DISEASE; CHICK EMBRYO; CHICKEN; COST CONTROL; CYTOKINE GENE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FOOD QUALITY; GENE; GENE IDENTIFICATION; IMMUNE RESPONSE; IN OVO VACCINATION; INFLAMMATION; LIVESTOCK; MEAT; NONHUMAN; POULTRY; REVIEW; ULCER; VACCINATION; ZOONOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIRDS; CYTOKINES; GENOME; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS; VACCINES;

AVES; GALLUS GALLUS;

EID: 9444235148     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2004.01295.x     Document Type: Review

References (58)

1. Bowersock TL. Evolving importance of biologics and novel delivery systems in the face of microbial resistance. AAPS Pharm. Sci. 2002; 4: 1-7.
2. Iovine NM, Blaser MJ. Antibiotics in animal feed and spread of resistant Campylobacter from poultry to humans. Emerg. Infect. Dis. 2004; 10: 1158-9.
3. Salisbury JG, Nicholls TJ, Lammerding AM, Turnidge J, Nunn MJ. A risk analysis framework for the long-term management of antibiotic resistance in food-producing animals. Int. J. Antimicrob. Agents 2002; 20: 153-64.
4. Bowersock TL, Martin S. Vaccine delivery to animals. Adv. Drug Deliv. Rev. 1999; 38: 167-94.
5. Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. Pharm. Biotechnol. 1995; 6: 229-48.
6. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998; 32: 155-72.
7. Cox JC, Coulter AR. Adjuvants, a classification and review of their modes of action. Vaccine 1997; 15: 248-56.
8. Steiner JW, Langer B, Schatz DL. The local and systemic effects of Freund's adjuvant and its fractions. Arch. Pathol. 1960; 70: 424-34.
9. Droual R, Bickford AA, Cutler GJ. Local reaction and serological response in commercial layer chickens injected intramuscularly in the leg with oil-adjuvanted Mycoplasma gallisepticum bacterin. Avian Dis. 1993; 37: 1001-1008.
10. Leenaars M, Koedam MA, Hendriksen CF, Claassen E. Immune responses and side effects of five different oil-based adjuvants in mice. Vet. Immunol. Immunopathol. 1998; 61: 291-304.
11. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants, a balance between toxicity and adjuvanticity. Vaccine 1993; 11: 293-306.
12. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 1980; 2: 370-83.
13. Foss DL, Murtaugh MP. Mechanisms of vaccine adjuvanticity at mucosal surfaces. Anim. Health Res. Rev. 2000; 1: 3-24.
14. Anderson KV, Jurgens G, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 1985; 42: 779-89.
15. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-83.
16. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003; 21: 335-76.
17. Qureshi ST, Medzhitov R. Toll-like receptors and their role in experimental models of microbial infection. Genes Immun. 2003; 4: 87-94.
18. Kensil CR. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996; 13: 1-55.
19. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 2001; 3: 15-24.
20. Fukui A, Inoue N, Matsumoto M et al. Molecular cloning and functional characterization of chicken toll-like receptors. A single chicken toll covers multiple molecular patterns. J. Biol. Chem. 2001; 276: 47 143-9.
21. Leveque G, Forgetta V, Morroll S et al. Allelic variation in TLR4 is linked to susceptibility to Salmonella enterica serovar Typhimurium infection in chickens. Infect. Immun. 2003; 71: 1116-24.
22. Dil N, Qureshi MA. Involvement of lipopolysaccharide related receptors and nuclear factor kappa B in differential expression of inducible nitric oxide synthase in chicken macrophages from different genetic backgrounds. Vet. Immunol. Immunopathol. 2002; 88: 149-61.
23. Odean MJ, Van Frane CM, derVieren M, Tomai MA, Johnson AG. Involvement of gamma interferon in antibody enhancement by adjuvants. Infect. Immun. 1990; 58: 427-32.
24. Bliss J, Maylor R, Stokes K, Murray KS, Ketchum MA, Wolf SF. Interleukin-12 as vaccine adjuvant. Characteristics of primary, recall, and long-term responses. Ann. NY Acad. Sci. 1996; 795: 26-35.
25. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 1996; 17: 138-46.
26. Mosmann TR, Li L, Hengartner H, Kagi D, Fu W, Sad S. Differentiation and functions of T cell subsets. Ciba Found. Symp. 1997; 204: 148-58.
27. Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc. Natl Acad. Sci. USA 1989; 86: 4240-43.
28. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 1995; 13: 399-415.
29. Rouse BT, Miller LS, Turtinen L, Moore RN. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2. J. Immunol. 1985; 134: 926-30.
30. Sundick RS, Gill-Dixon C. A cloned chicken lymphokine homologous to both mammalian IL-2 and IL-15. J. Immunol. 1997; 159: 720-25.
31. Hughes HP, Campos M, van Drunen Littel-van den Hurk S et al. Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV. Vaccine 1992; 10: 226-30.
32. Reddy DN, Reddy PG, Xue W, Minocha HC, Daley MJ, Blecha F. Immunopotentiation of bovine respiratory disease virus vaccines by interleukin-1 beta and interleukin-2. Vet. Immunol. Immunopathol. 1993; 37: 25-38.
33. Pighetti GM, Sordillo LM. Enhanced antigen-specific responses in bovine mammary glands following administration of interleukin-2. J. Dairy Sci. 1995; 78: 528-37.
34. Honda Y, Waithaka M, Taracha EL, Duchateau L, Musoke AJ, McKeever DJ. Delivery of the Theileria parva p67 antigen to cattle using recombinant vaccinia virus: IL-2 enhances protection. Vaccine 1998; 16: 1276-82.
35. Weinberg A, Merigan TC. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. J. Immunol. 1988; 140: 294-9.
36. Kawashima K, Platt KB. The effect of human recombinant interleukin-2 on the porcine immune response to a pseudorabies virus subunit vaccine. Vet. Immunol. Immunopathol. 1989; 22: 345-53.
37. Good MF, Pombo D, Lunde MN et al. Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2. J. Immunol. 1988; 141: 972-7.
38. Kawamura H, Rosenberg SA, Berzofsky JA. Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J. Exp. Med. 1985; 162: 381-6.
39. Heath AW, Devey ME, Brown IN, Richards CE, Playfair JH. Interferon-gamma as an adjuvant in immunocompromised mice. Immunology 1989; 67: 520-24.
40. Cao M, Sasaki O, Yamada A, Imanishi J. Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine 1992; 10: 238-42.
41. Staruch MJ, Wood DD. The adjuvanticity of interleukin 1 in vivo. J. Immunol. 1983; 130: 2191-4.
42. Reddy PG, Blecha F, Minocha HC et al. Bovine recombinant interleukin-2 augments immunity and resistance to bovine herpesvirus infection. Vet. Immunol. Immunopathol. 1989; 23: 61-74.
43. Babiuk LA, Sordillo LM, Campos M, Hughes HP, Rossi-Campos A, Harland R. Application of interferons in the control of infectious diseases of cattle. J. Dairy Sci. 1991; 74: 4385-98.
44. Nash AD, Lofthouse SA, Barcham GJ et al. Recombinant cytokines as immunological adjuvants. Immunol. Cell Biol. 1993; 71: 367-79.
45. Schijns VE, Weining KC, Nuijten P, Rijke EO, Staeheli P. Immunoadjuvant activities of E. coli- and plasmid-expressed recombinant chicken IFN-alpha/beta, IFN-gamma and IL-1beta in 1-day- and 3-week-old chickens. Vaccine 2000; 18: 2147-54.
46. Karaca K, Sharma JM, Winslow BJ et al. Recombinant fowlpox viruses coexpressing chicken type 1 IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses. Vaccine 1998; 16: 1496-503.
47. Min W, Lillehoj HS, Burnside J, Weining KC, Staeheli P, Zhu JJ. Adjuvant effects of IL-1beta, IL-2, 1L-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine 2001; 20: 267-74.
48. Hilton LS, Bean AG, Kimpton WG, Lowenthal JW. Interleukin-2 directly induces activation and proliferation of chicken T cells in vivo. J. Interferon Cytokine Res. 2002; 22: 755-63.
49. Lowenthal JW, O'Neil TE, Broadway M et al. Co-administration of IFN-gamma enhances antibody responses in chickens. J. Interferon Cytokine Res. 1998; 18: 617-22.
50. Leutz A, Beug H, Graf T. Purification and characterization of cMGF, a novel chicken myelomonocytic growth factor. EMBO J. 1984; 3: 3191-7.
51. York JJ, Strom AD, Connick TE, McWaters PG, Boyle DB, Lowenthal JW. In vivo effects of chicken myelomonocytic growth factor: delivery via a viral vector. J. Immunol. 1996; 156: 2991-7.
52. Djeraba A, Musset E, Lowenthal JW et al. Protective effect of avian myelomonocytic growth factor in infection with Marek's disease virus. J. Virol. 2002; 76: 1062-70.
53. Reddy SK, Sharma JM, Ahmad J et al. Protective efficacy of a recombinant herpesvirus of turkeys as an in ovo vaccine against Newcastle and Marek's diseases in specific-pathogen-free chickens. Vaccine 1996; 14: 469-77.
54. Rautenschlein S, Sharma JM, Winslow BJ, McMillen J, Junker D, Cochran M. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants. Vaccine 1999; 18: 426-33.
55. Sharma JM, Burmester BR. Resistance to Marek's disease at hatching in chickens vaccinated as embryos with the turkey herpesvirus. Avian Dis. 1982; 26: 134-49.
56. Sharma JM. Embryo vaccination with infectious bursal disease virus alone or in combination with Marek's disease vaccine. Avian Dis. 1985; 29: 1155-69.
57. Ahmad J, Sharma JM. Evaluation of a modified-live virus vaccine administered in ovo to protect chickens against Newcastle disease. Am. J. Vet. Res. 1992; 53: 1999-2004.
58. Johnston PA, Liu H, O'Connell T et al. Applications in in ovo technology. Poultry Sci. 1997; 76: 165-78.